References
- Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: Insight into
CFTR pathophysiology and pharmacotherapy. Clin Biochem.
2012;45:1132–1144.
- Boucher RC. An overview of the pathogenesis of cystic fibrosis lung
disease. Adv Drug Deliv Rev. 2002;54:1359–1371.
- Ong T, Ramsey BW. New therapeutic approaches to modulate and correct
cystic fibrosis transmembrane conductance regulator. Pediatr Clin
North Am. 2016; 63:751–764.
- Davies JC, Alton EW, Bush A. Cystic fibrosis. Br Med J. 2007;
335(7632):1255–1259.
- Spoonhower KA, Davis PB. Epidemiology of cystic fibrosis. Clin Chest
Med. 2016;37:1–8.
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N. Engl J Med.
2005;352(19):1992-2001
- Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Accurso
FJ. Cystic Fibrosis Foundation evidence-based guidelines for
management of infants with cystic fibrosis. J Pediatr. 2009;155(Suppl.
6):S73–S93.
- Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Davis
SD. Clinical practice guidelines from the Cystic Fibrosis Foundation
for preschoolers with cystic fibrosis. Pediatrics. 2016;137:1–26.
- Edmondson C, Davies JC. Current and future treatment options for
cystic fibrosis lung disease: Latest evidence and clinical
implications. Ther Adv Chronic Dis 2016;7:170–183
- Pettit RS, Fellner C. CFTR modulators for the treatment of cystic
fibrosis. PT. 2014;39:500–511.
- Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR
modulators: Progress and challenges. Pediatr Pulmonol.
2017;52(S48):S4–S14.
- Gramegna
A, Contarini M, Aliberti
S, Casciaro
R, Blasi
F, Castellani
C. From Ivacaftor to Triple Combination: A Systematic Review of
Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
Int J Mol
Sci. 2020; 21(16): 5882.
- Salvatore D, Padoan R, Buzzetti R, Amato A, Giordani B, Ferrari G,
Majo F. Patients
with cystic fibrosis having a residual function mutation: Data from
the Italian registry. Pediatr Pulmonol. 2019;54(2):150-157.
- Casciaro
R, Costa
S, Dang
P, Majo
F, Ros M. Lumacaftor/ivacaftor combination therapy for cystic
fibrosis: A nationwide survey among clinicians. Clin Respir J. 2018
Apr;12(4):1767-1768
- Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M,
Accurso FJ, Wolter DJ, Cooke G, et al. Restoring Cystic Fibrosis
Transmembrane Conductance Regulator Function Reduces Airway Bacteria
and Inflammation in People with Cystic Fibrosis and Chronic Lung
Infections. Am J Respir Crit Care Med. 2017;195(12):1617-1628.
- Ronan N, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M,
O’Callaghan G, Shanahan F, Murphy DM, O’Connor OJ, et al. CORK Study
in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT
Scores After CFTR Modulation With Ivacaftor. Chest.
2018;153(2):395-403.
- Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr.
Computed tomography correlates with improvement with ivacaftor in
cystic fibrosis patients with G551D mutation J Cyst Fibros. 2015
Jan;14(1):84-9.
- Brody A, Nagle S, Hug C, Marigowda G, Waltz D, Goldin J, Ratjen F,
Wang L. S93 Effect of lumacaftor/ivacaftor on total, bronchiectasis,
and air trapping computed tomography (ct) scores in children
homozygous for f508del-cftr : exploratory imaging substudy.
Thorax. 2017;72:A57.
- Altes TA, Johnson M, Fidler M, Botfield M, Tustison NJ, Leiva-Salinas
C, de Lange EE, Froh D, Mugler JP 3rd. Use of hyperpolarized helium-3
MRI to assess response to ivacaftor treatment in patients with cystic
fibrosis J Cyst Fibros. 2017;16(2):267-274.
- Davies JC,
Wainwright
CE, Sawicki GS,
Higgins MN, Campbell
D, Harris
C, Panorchan
P, Haseltine
E, Tian
S, Rosenfeld
M. Ivacaftor in infants aged 4 to <12 months with cystic
fibrosis and a gating mutation: Results of a 2-part Phase 3 clinical
trial. Am J Respir Crit Care Med. 2020 Oct 7. doi:
10.1164/rccm.202008-3177OC.
- Rubin JL, O’Callaghan L, Pelligra C, Konstan MW, Ward A, Ishak JK,
Chandler C, Liou TG. Modeling long-term health outcomes of patients
with cystic fibrosis homozygous for F508del-CFTR treated with
lumacaftor/ivacaftor. Ther Adv Respir Dis. 2019;13:1753466618820186.
- Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C,
Konstan MW, Sawicki GS, Sewall A, Nyangoma S, et al. Data from the US
and UK cystic fibrosis registries support disease modification by CFTR
modulation with ivacaftor. Thorax. 2018;73(8):731-740